184 related articles for article (PubMed ID: 16580897)
1. The beneficial effect of intravenous zoledronic acid therapy following an acute stroke in rats.
Lee JI; Kim HW; Rhee WI; Park JH; Lim SH; Im S; Ko YJ
Bone; 2006 Aug; 39(2):377-82. PubMed ID: 16580897
[TBL] [Abstract][Full Text] [Related]
2. Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion.
Chen F; Dai Z; Kang Y; Lv G; Keller ET; Jiang Y
Osteoporos Int; 2016 Apr; 27(4):1469-1476. PubMed ID: 26556733
[TBL] [Abstract][Full Text] [Related]
3. A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.
Gasser JA; Green JR; Shen V; Ingold P; Rebmann A; Bhatnagar AS; Evans DB
Bone; 2006 Oct; 39(4):787-95. PubMed ID: 16844441
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.
Liu J; Xu K; Wen G; Guo H; Li S; Wu X; Dai R; Sheng Z; Liao E
Bone; 2008 May; 42(5):950-9. PubMed ID: 18337202
[TBL] [Abstract][Full Text] [Related]
5. Does exercise modify the effects of zoledronic acid on bone mass, microarchitecture, biomechanics, and turnover in ovariectomized rats?
Lespessailles E; Jaffré C; Beaupied H; Nanyan P; Dolléans E; Benhamou CL; Courteix D
Calcif Tissue Int; 2009 Aug; 85(2):146-57. PubMed ID: 19609736
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
[TBL] [Abstract][Full Text] [Related]
7. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
8. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
[TBL] [Abstract][Full Text] [Related]
9. Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2.
Otomo H; Sakai A; Ikeda S; Tanaka S; Ito M; Phipps RJ; Nakamura T
J Bone Miner Metab; 2004; 22(5):404-14. PubMed ID: 15316861
[TBL] [Abstract][Full Text] [Related]
10. Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction.
Yoshida Y; Moriya A; Kitamura K; Inazu M; Okimoto N; Okazaki Y; Nakamura T
J Bone Miner Res; 1998 Jun; 13(6):1011-22. PubMed ID: 9626633
[TBL] [Abstract][Full Text] [Related]
11. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats.
Bauss F; Lalla S; Endele R; Hothorn LA
J Rheumatol; 2002 Oct; 29(10):2200-8. PubMed ID: 12375334
[TBL] [Abstract][Full Text] [Related]
12. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
13. Skeletal effects of zoledronic acid in an animal model of chronic kidney disease.
Allen MR; Chen NX; Gattone VH; Chen X; Carr AJ; LeBlanc P; Brown D; Moe SM
Osteoporos Int; 2013 Apr; 24(4):1471-81. PubMed ID: 22907737
[TBL] [Abstract][Full Text] [Related]
14. Influence of early zoledronic acid administration on bone marrow fat in ovariectomized rats.
Li GW; Xu Z; Chang SX; Zhou L; Wang XY; Nian H; Shi X
Endocrinology; 2014 Dec; 155(12):4731-8. PubMed ID: 25243855
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
Kim JE; Ahn JH; Jung KH; Kim SB; Kim HJ; Lee KS; Ro JS; Park YH; Ahn JS; Im YH; Im SA; Lee MH; Kim SY
Breast Cancer Res Treat; 2011 Jan; 125(1):99-106. PubMed ID: 20922564
[TBL] [Abstract][Full Text] [Related]
16. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
Hornby SB; Evans GP; Hornby SL; Pataki A; Glatt M; Green JR
Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
[TBL] [Abstract][Full Text] [Related]
19. Effect of zoledronic acid on incorporation of a bioceramic bone graft substitute.
Välimäki VV; Moritz N; Yrjans JJ; Vuorio E; Aro HT
Bone; 2006 Mar; 38(3):432-43. PubMed ID: 16338190
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia.
Iwata K; Li J; Follet H; Phipps RJ; Burr DB
Bone; 2006 Nov; 39(5):1053-1058. PubMed ID: 16807159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
